Neuralstem Announces Proposed Public Offering of Common Stock and Warrants

Neuralstem Announces Top-line Phase 2 Data of NSI-189 for Major Depressive Disorder

Neuralstem Added to the Russell Microcap® Index

Neuralstem Reports Last Subject Out in Phase 2 Trial of NSI-189 for Major Depressive Disorder

Neuralstem Reports First Quarter 2017 Fiscal Results Provides Clinical and Business Update

Neuralstem Expands Phase 1 Safety Trial of NSI-566 Neural Stem Cells in Spinal Injury

Neuralstem Reports Year End 2016 Fiscal Results and Business Update

Neuralstem to Present at Oppenheimer 27th Annual Healthcare Conference on March 21

Neuralstem Announces Publication of NSI-566 Data in a Rodent Model of Traumatic Brain Injury

Neuralstem to Present at 29th Annual ROTH Conference